2-(4-methylbenzylamino)acetaldehyde dimethyl acetal | 54879-84-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methylbenzylamino)acetaldehyde dimethyl acetal
• 英文别名: 2,2-dimethoxy-N-[(4-methylphenyl)methyl]ethanamine
• CAS: 54879-84-4
• 化学式: C₁₂H₁₉NO₂
• mdl: MFCD12148389
• 分子量: 209.288
• InChiKey: JHYYZIHPXNXKKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-methylbenzylamino)acetaldehyde dimethyl acetal 在 氯磺酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 22.0h， 生成 6-methylisoquinoline 2-oxide
  参考文献：
  名称：

  使用 1-重氮萘醌的 Cu(II)-催化构建杂二芳基化合物：合成 QUINOX 和相关 P,N 配体的一般策略

  摘要：

  开发了一种有效且直接的方法，用于在廉价的 Cu(II) 催化下使用容易获得的N-氧化物和重氮萘醌合成杂二芳基化合物。所开发的方法以简单的方式提供了 QUINOX 和相关同类物。以高位点选择性实现了范围广泛的重要杂二芳基化合物。合成的萘酚被转化为特权相关的 P,N 配体。合适的拆分方法可以直接提供相应的轴向手性杂二芳基化合物。

  DOI：

  10.1021/acs.orglett.2c00127
• 作为产物：
  描述：

  N-(2,2-dimethoxyethyl)-1-(4-methylphenyl)methanimine 在 sodium tetrahydroborate 、 水 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 以100%的产率得到2-(4-methylbenzylamino)acetaldehyde dimethyl acetal
  参考文献：
  名称：

  WO2007/76092

  摘要：

  公开号：

文献信息

• Nitrogen-containing bicyclic heteroaryl compounds and methods of use
  申请人：De Morin F. Frenel

  公开号：US20070185324A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R 1 is and A 1 , A 2 , A 3 , A 4 , X, Z, Z′, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新的化合物类别，能够调节Raf激酶，因此有助于治疗由Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的疾病。该化合物具有通用的I式，其中R1为，A1、A2、A3、A4、X、Z、Z'、R2、R3、R4、R5和R6在此被定义。本发明还包括制备本发明化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。
• NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：De Morin Frenel F.

  公开号：US20110251199A1

  公开（公告）日：2011-10-13

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I and A 1 , A 2 , A 3 , A 4 , X, Z, Z′, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涵盖了一种新的化合物类别，能够调节Raf激酶，因此可用于治疗Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的疾病。该化合物具有一般的I式，其中A1、A2、A3、A4、X、Z、Z'、R1、R2、R3、R4、R5和R6在此定义。本发明还涵盖了制备该化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。
• RAF KINASE MODULATORS AND METHODS OF USE
  申请人：Smith Adrian L.

  公开号：US20100324047A1

  公开（公告）日：2010-12-23

  The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , bond B, X, rings Z 1 and Z 2 , R 1 and R 3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新的化合物类别，能够调节Raf激酶的活性，因此可用于治疗Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的病症。该化合物具有一般式（I），其中A1、A2、A3、A4、A5、A6、A7、A8、A9、键B、X、环Z1和Z2、R1和R3在此定义。本发明还包括制备该化合物的中间体和方法，以及用于治疗Raf激酶介导疾病的药物组合物。
• Ultrasound assisted one-pot synthesis of benzo-fused indole-4,9-dinones from 1,4-naphthoquinone and α-aminoacetals
  作者：Quang H. Luu、Jorge D. Guerra、Cecilio M. Castañeda、Manuel A. Martinez、Jong Saunders、Benjamin A. Garcia、Brenda V. Gonzales、Anushritha R. Aidunuthula、Shizue Mito

  DOI：10.1016/j.tetlet.2016.04.031

  日期：2016.5

  A one-pot synthesis of benzo[f]indole-4,9-diones from 1,4-naphthoquinone with alpha-aminoacetals has been developed. This method provides a straightforward synthesis of benzo[f]indole-4,9-diones via intramolecular nucleophilic attack of aminoquinones to aldehydes under mild reaction conditions. The detailed mechanism was also investigated. (C) 2016 Elsevier Ltd. All rights reserved.
• Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、James S. Frazee、Stephen T. Ross、Joyce Wawro、Merrie Wise、Kathryn E. Flaim、John L. Sawyer

  DOI：10.1021/jm00386a008

  日期：1987.3

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.